Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | MPO | P05164 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | DDO | Q99489 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7288932 | 0.74 | HPGD (0.35) | CA12DAO | |
| SCHEMBL4478128 | 0.74 | AHR (0.42) | CA12CA9GPR84DAO | |
| SCHEMBL21053251 | 0.72 | GPR84 (0.44) | CA12CA9GPR84MPOSLC6A4 | |
| SCHEMBL7278500 | 0.69 | IDO1 (0.32) | — | |
| SCHEMBL7279169 | 0.69 | GABRA1 (0.39) | DAODDO | |
| SCHEMBL835945 | 0.67 | TDP1 (0.44) | — | |
| SCHEMBL9741763 | 0.66 | DAO (0.41) | DAOFEN1 | |
| SCHEMBL7289074 | 0.66 | DAO (0.41) | DAO | |
| SCHEMBL1966793 | 0.65 | FFAR1 (0.41) | CA12CA9GPR84FFAR1DAO | |
| SCHEMBL3929859 | 0.65 | TNF (0.35) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114981247-A | Piperazine compounds for inhibiting CPS1 | 卫材R&D管理有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| US-11891386-B2 | Indole compounds and their use | ARIAGEN, INC. (CA) | 2024-02-06 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| CN-116368146-A | Novel ligands for asialoglycoprotein receptors | 赛诺菲 | 2023-06-30 | — | — | CN | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230054194-A1 | Methods of Treating Cancer | ARIAGEN, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220389002-A1 | Chiral Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-11459322-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11390621-B2 | Chiral indole compounds and their use | ARIAGEN, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-4870087-A | Indole containing, 2-thienyl-1,2,3,6-tetrahydropyridyls and their pharmaceutical use | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-09-26 | — | — | US | disclosed |
| US-4824852-A | Substituted indole compounds which have useful effects on the central nervous system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-04-25 | — | — | US | disclosed |
| US-4740602-A | Indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-04-26 | — | — | US | disclosed |
| EP-0121716-B1 | INDOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 1987-12-09 | — | — | EP | disclosed |
| EP-0206225-A2 | Indole derivatives | MERCK PATENT GmbH (DE) | 1986-12-30 | — | — | EP | disclosed |
| US-4617309-A | Sulfur-containing indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | disclosed |
| EP-0121716-A1 | Indole derivatives | MERCK PATENT GmbH (DE) | 1984-10-17 | — | — | EP | disclosed |
| EP-0007399-B1 | INDOLYLALKYL AMINES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR THEIR MANUFACTURE | MERCK PATENT GmbH (DE) | 1982-01-20 | — | — | EP | disclosed |
| US-4251538-A | Indolealkylamines and processes for their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-02-17 | — | — | US | disclosed |
| EP-0007399-A1 | Indolylalkyl amines, pharmaceutical preparations containing them and process for their manufacture | MERCK PATENT GmbH (DE) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459322-B2 | Indole compounds and their use | IDO1, IDO2, INMT | CA12 1908/4885CA9 2210/4885GPR84 801/4885 |
| US-11891386-B2 | Indole compounds and their use | IDO1, IDO2, INMT | CA12 1908/4885CA9 2210/4885GPR84 801/4885 |
| US-20220389002-A1 | Chiral Indole Compounds and Their Use | IDO1, IDO2, INMT | CA12 1043/4885CA9 937/4885GPR84 300/4885 |
| US-20230054194-A1 | Methods of Treating Cancer | TP53, MSH2, PDCD1 | CA12 449/4885CA9 822/4885GPR84 3883/4885 |
| US-11390621-B2 | Chiral indole compounds and their use | IDO1, IDO2, INMT | CA12 1043/4885CA9 937/4885GPR84 300/4885 |
| US-20230145074-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | CA12 1908/4885CA9 2210/4885GPR84 801/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | CA12 4458/4885CA9 4667/4885GPR84 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.